La vendita allo scoperto per DigiAsia dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di DigiAsia. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

DigiAsia (NASDAQ:FAAS) Azioni, Report sulle vendite allo scoperto

DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.

DigiAsia Corp

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) with a Buy and maintains $8 price target.

News

Price Target

Reiteration

Analyst Ratings

GANX

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

D. Boral Capital analyst Jesse Sobelson maintains EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) with a Buy and lowers the price target from $6 to $4.5.

EONR

D. Boral Capital Maintains Buy on EON Resources, Lowers Price Target to $4.5

Baird analyst Justin Kleber maintains Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) with a Outperform and raises the price target from $35 to $40.

CHWY

Baird Maintains Outperform on Chewy, Raises Price Target to $40

WIIM

CGTX

Cognition Therapeutics shares are trading higher after the company provided an update on a biomarker analysis from the Phase 2 SHINE study in mild-to-moderate Alzheimer's disease.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

ABEO

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

Northland Capital Markets analyst Ted Jackson downgrades Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) from Outperform to Market Perform and lowers the price target from $9 to $5.

Downgrades

Northland Capital Markets Downgrades Xos to Market Perform, Lowers Price Target to $5

WestPark Capital analyst Paul Rodriguez reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Hold.

CRWD

WestPark Capital Reiterates Hold on CrowdStrike Holdings

Rosenblatt analyst Barton Crockett maintains Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) with a Buy and raises the price target from $7.7 to $10.3.

QUAD

Rosenblatt Maintains Buy on Quad/Graphics, Raises Price Target to $10.3

"Alarum's fourth quarter 2024 revenues are estimated at $7.5 million ±3% and Adjusted EBITDA for the fourth quarter 2024 is expected to range from $1.3 million to $1.7 million."

Guidance

ALAR

Alarum Technologies Expects Q4 Revenue Of $7.5M ±3% Vs $7.48M Est

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) with a Buy and lowers the price target from $8 to $5.

CARM

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $5

ELAB

Elevai Labs shares are trading lower after the company announced a 1-for-200 reverse stock split.

SNOW

Snowflake shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform.

UXIN

Uxin shares are trading higher after the company reported Q2 sales of $70.85 million, up from $48.80 million year-over-year.

Macy's shares are trading lower after the company delayed its Q3 earnings release and conference call, citing an issue related to delivery expenses in one of its accrual accounts, prompting an independent investigation.

BBWI

Bath & Body Works shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its 2024 guidance.

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $325 to $385.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Raises Price Target to $385

The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active ulcerative colitis.

Biotech

Health Care

General

Palatin Technologies Has Completed Enrollment In Its Phase 2 Study Of PL8177 For Ulcerative Colitis, The Last Patient Visit Is Expected To Occur In Q1 Of 2025, With Topline Data Expected Shortly Thereafter

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announces Price Target of $80.

Initiation

SRPT

HC Wainwright & Co. Initiates Coverage On Sarepta Therapeutics with Sell Rating, Announces Price Target of $80

Cognition Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker(1) analysis from the Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau217(2) . Several blood-based measures of Alzheimer's disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients. These data provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system. &nbsp;

Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology

Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.05 by 300 percent. The company reported quarterly sales of $7.194 million which beat the analyst consensus estimate of $7.000 million by 2.77 percent. This is a 6.58 percent increase over sales of $6.750 million the same period last year.

Earnings

Earnings Beats

Alarum Technologies Q3 2024 Adj. EPS $0.20 Beats $0.05 Estimate, Sales $7.194M Beat $7.000M Estimate

Digiasia Corp. (FAAS) has released an update. DigiAsia Corp. has announced the launch of ANDITA, an advanced AI-driven initiative designed to boost...

DigiAsia Unveils AI Initiative for MSME Growth

MINM, LIDR among major tech gainers; SYTA, WDAY among losers

DigiAsia announces execution of agreement for convertible note financing with Helena Partners

DigiAsia (FAAS) has released an update. DigiAsia's latest news release contains no text content, consisting solely of placeholder image tags, which...

DigiAsia News Release Lacks Content

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
In the last few years, technological advancements in the fintech sector have put several <a href="https://investorplace.com/industries/financial/fintech/">fintech stocks</a> to buy in the limelight.&nbsp;



For the uninitiated, fintech refers to companies that offer technology solutions for money management. That includes mobile banking or trading apps, e-wallets and peer-to-peer payment platforms.&nbsp;



And while fintech&rsquo;s relevance has surged, the last few years have been challenging for companies in the space. Macroeconomic uncertainties and a decline in fintech funding have caused many to struggle to stay afloat. As a result, many fintech stocks are trending lower, with some at 52-week lows.&nbsp;



Nevertheless, the future of fintech remains optimistic. In an increasingly cashless society, these companies can shape consumer financial habits and transform the financial ecosystem. The data reflects this positive sentiment with the fintech market expected to grow to <a href="https://www.fintechfutures.com/techwire/fintech-market-size-projected-to-grow-to-882-billion-by-2030-as-advanced-technologies-services-expand/">$882 billion by 2030.</a>&nbsp;



This means investors willing to weather the short-term headwinds have the opportunity to capitalize on the long-term gains. As such, companies with high growth potential trading near 52-week lows offer a great entry point.&nbsp;



<h2>DigiAsia (FAAS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/fintech-300x169.jpg" alt="Light bulb on tablet and Stock graph and business technology icon with abstract electronic circuit background. best fintech stocks to buy. Top Fintech Stocks to Buy"><div>Source: Shutterstock</div></div>DigiAsia (NASDAQ:<a href="https://investorplace.com/stock-quotes/faas-stock-quote/">FAAS</a>) is a fintech-as-a-service (FaaS) platform that offers a range of financial solutions. These include digital wallets, supply chain payments and a banking-as-a-service (BaaS) platform. The company&rsquo;s premise is to support the financial needs of its partners with low-cost mass-market products.



Its shares may be trading lower but its strong market position offers tremendous growth potential. Since its inception, the company has forged several strategic partnerships to drive its expansion. Some of its notable partners include Mastercard (NYSE:<a href="https://investorplace.com/stock-quotes/ma-stock-quote/">MA</a>) in Jakarta, Western Union (NYSE:<a href="https://investorplace.com/stock-quotes/wu-stock-quote/">WU</a>) and Starbucks (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbux-stock-quote/">SBUX</a>). DigiAsia also signed a deal with DBS Bank (OTCMKTS:<a href="https://investorplace.com/stock-quotes/dbsdy-stock-quote/">DBSDY</a>), the largest bank in South East Asia to disburse merchant loans through its platform.&nbsp;



In more recent news, the company <a href="https://finance.yahoo.com/news/digiasia-corp-advances-ai-solutions-200500937.html">secured the allocation</a> of an initial shipment of 5,120 Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) H200 GPUs. As part of the deal, DigiAsia will be responsible for deploying and developing advanced AI solutions in Southeast Asia, the Middle East and India. The partnership will help enhance the efficiency of DigiAsia&rsquo;s infrastructure while capitalizing on a $300 billion financial services market.&nbsp;



With an exciting deal in the pipeline and shares hovering at the 52-week low, FAASstands out as one of the best fintech stocks to buy. The company provides investors with the perfect blend of valuation, innovation and stability in the fintech sector.



<h2>DLocal (DLO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/dlo1600-300x169.png" alt="Mobile phone with webpage of Uruguayan payment company dLocal Limited (DLO) on screen in front of logo Focus on top-left of phone display"><div>Source: Wirestock Creators / Shutterstock.com</div></div>DLocal (NASDAQ:<a href="https://investorplace.com/stock-quotes/dlo-stock-quote/">DLO</a>) is a fintech play that certainly deserves more attention. The Latin American-based fintech platform serves as a bridge between global businesses and emerging markets. Through the help of dLocal&rsquo;s cross-border payments platform, businesses can transact in countries with their own payment ecosystems. The platform provides access to 40 markets across Latin America, South East Asia and Africa.&nbsp;



Fundamentally speaking, dLocal remains a solid play. In its recent earnings, the company posted <a href="https://dlocal.gcs-web.com/news-releases/news-release-details/dlocal-reports-2024-first-quarter-financial-results">revenue at $184 million,</a> up 34% year-over-year (YoY). This was fueled by a 49% rise in total payment volumes (TPV). The TPV growth certainly speaks to the company&rsquo;s ability to remain competitive and provide value through its solutions. However, shares dived following earnings on <a href="https://www.benzinga.com/news/earnings/24/05/38849832/why-dlocal-stock-is-plunging-wednesday">weaker-than-expected results.</a>&nbsp;



Nevertheless, DLO stock remains an appealing buy for several reasons. One, the company&rsquo;s solution makes it significantly easier for global businesses to sell in emerging markets. Second, it has established a presence amongst high-profile customers including Amazon (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/">AMZN</a>), Microsoft (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>) and Shopify (NYSE:<a href="https://investorplace.com/stock-quotes/shop-stock-quote/">SHOP</a>). Third, DLO stock is down 54% this year and trading near its 52-week low. This makes it one of the best fintech stocks to buy for bargain-hunting investors seeking long-term returns.&nbsp;



<h2>SoFi Technologies (SOFI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/sofi1600-1-300x169.png" alt="SoFi Technologies, Inc logo with stock market chart background. is an American online personal finance company and online bank."><div>Source: Poetra.RH / Shutterstock.com</div></div>Despite a steep drop in its price,, SoFi Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) remains an attractive option for investors seeking a high-growth name. The digital banking platform boasts a loyal customer base with its easy-to-use app that caters to a young audience. This enabled SoFi to scale its business and generate attractive returns. The numbers reflect its success story.



In the first quarter, <a href="https://s27.q4cdn.com/749715820/files/doc_financials/2024/q1/Q1-2024-Earnings-Release-6.pdf">revenue was up $581 million,</a> a 26% increase YoY. This was fueled by a 54% rise in tech platforms and financial services revenue. Adjusted EBITDA was up 91%, while new member additions grew 44% from the prior year. Additionally, the number of products used by its customers also grew by 38% to 11.8 million. And while the numbers are certainly impressive, SOFI stock plunged on a <a href="https://www.fool.com/investing/2024/04/29/why-sofi-technologies-stock-dropped-10-on-earnings/">weak second-quarter outlook.</a>&nbsp;



While slowing growth levels are certainly a red flag, SoFi&rsquo;s long-term prospects remain strong. The company&rsquo;s diversified business and innovative technology provide a steady runway for growth. Moreover, the stock is attractively priced and hit its 52-week low earlier this month.



Investors willing to weather the short-term headwinds for long-term gains will find SOFI one of the top fintech stocks to buy this month.&nbsp;



On the date of publication, Divya Premkumar&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor held a LONG position in SBUX.
<div>Divya has a background in finance and accounting and has worked in FP&amp;A roles at Fortune 500 companies. She is an avid reader and enjoys writing on a variety of topics including stocks, crypto, blockchain and global policy.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-fintech-stocks-to-buy-at-52-week-lows-in-july/">3 Fintech Stocks to Buy at 52-Week Lows in July</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Fintech Stocks to Buy at 52-Week Lows in July

DigiAsia (FAAS) has released an update. DigiAsia has entered into an amendment agreement with Greenhaven Road Capital Fund affecting the terms of a...

DigiAsia Amends Note Terms with Greenhaven

DigiAsia (FAAS) has released an update. DigiAsia, Indonesia's leading Fintech-as-a-Service provider, plans to catalyze enterprise growth with its c...

DigiAsia's Strategic Expansion in Southeast Asia's Fintech

PayMate looks to buy DigiAsia's unit

PayMate looks to buy DigiAsia

DigiAsia (FAAS) has released an update. DigiAsia Corp. has entered into a forbearance agreement with Helena Special Opportunities LLC and Scieniti ...

Comments

DigiAsia

Vendite allo scoperto

DigiAsia (NASDAQ:FAAS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO